FRESCO-2: Analyzing Fruquintinib for Refractory Metastatic Colorectal Cancer
By Cathy Eng, MD, FACP, FASCO - Last Updated: March 19, 2025Cathy Eng, MD, FACP, FASCO, Vanderbilt University Medical Center, provides an in-depth review of the FRESCO-2 trial that examined the efficacy of fruquintinib for refractory metastatic colorectal cancer.
Advertisement
Dr. Eng discusses how the trial results differ from the original FRESCO trial, and how fruquintinib differs from other VEGFR inhibitors.
Advertisement
Related Posts
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.